Essential Thrombocythemia: What Patients Should Know (2022) | Top MPN Specialist Dr. Ruben Mesa

The landscape of treatments in MPNs like essential thrombocythemia is rapidly changing, with many emerging therapies and drugs in clinical studies. We talk to MPNs specialist, Dr. Ruben Mesa, who helps us translate into laymans’ terms some important updates to watch out for in 2022. Featuring: Dr. Ruben Mesa, Driector of UT Health San Antonio MD Anderson Cancer Center, Myeloproliferative Neoplasms (MPNs) Specialist In this Series: Dr. Mesa covers the latest updates following the biggest blood cancer/disease conference (ASH) held at the end of 2021 that looked forward to emerging and promising treatments in clinical trials in 2022 and beyond. Full story & transcript → https://www.thepatientstory.com/medic... The interview has only been edited for clarity. Join Our Community: Website : https://www.thepatientstory.com/ Facebook: @ThePatientStory Instagram: @ThePatientStory Twitter: @patient_story ____________________________ Contents of this video: 00:00 - Intro 00:58 - The recent history of MPNs and treatments 05:18 - Treatment option for essential thrombocythemia (ET) 9:20 - Access to the ropegylated interferon 10:06 - How would patients get the IMG 7289 or bomedemstat? 11:46 - The promise of not just controlling symptoms but treatment to impact the disease 12:27 - Last message for ET patients and caregivers ____________________________ #ThePatientStory #bloodcancer #blooddisease #hematology #oncology #MPN #myeloproliferativeneoplasms #essentialthrombocythemia #polycythemiavera #clinicaltrials #relapsedrefractory #Patientcare #cancertreatment #Cartcelltherapy